Sign in with Google. Opens in new tab
ENTITY
Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals (PAR AU)

21
Analysis
Health CareAustralia
Paradigm Biopharmaceuticals Limited operates as a biopharmaceutical company. The Company develops PPS drug to treat respiratory diseases such as allergic asthma, allergic rhinitis, and chronic obstructive pulmonary. Paradigm Biopharmaceuticals offers its services in Australia.
more
08 Dec 2024 14:45

Paradigm Biopharmaceuticals (PAR AU): Fund Raising Amidst Pipeline Progress Raises Conviction

Paradigm Biopharmaceuticals has requested a trading halt pending an announcement in relation to a capital raising. Normal trading will resume on...

Logo
803 Views
Share
16 Jul 2024 15:44

Australian Biotech Companies Amid Talk of Likely Interest Rate Cut

​RBA keeps interest rates steady at 4.35%, while economists predict possible cut to 4.10% in 4Q24. Australian biotech companies should be in focus...

Logo
367 Views
Share
18 Oct 2023 15:27

Paradigm Biopharmaceuticals (PAR AU): Positive Result from Phase 2 Trial; Satisfactory Cash Position

​Phase 2 trial shows that iPPS treats osteoarthritis symptoms as well as preserves/regenerates joint tissues, potentially leading to greater...

Logo
437 Views
Share
17 Aug 2022 13:58

Paradigm Biopharmaceuticals (PAR AU): Comfortable Funding Position Through 2024

Paradigm is raising $66M via a fully underwritten placement that will entail a proforma cash position of $108.5M to fund it into 2024. The company...

Logo
377 Views
Share
14 Mar 2022 13:36

Paradigm Biopharmaceuticals (PAR AU): Concerns Persist Amid Deteriorating Financials

Paradigm’s widened net loss and depreciated cash balance raise our concern on its capability of conducting clinical activities and regulatory...

Logo
291 Views
Share
x